|Bid||283.00 x 200|
|Ask||283.50 x 100|
|Day's Range||280.02 - 283.00|
|52 Week Range||244.28 - 333.65|
|PE Ratio (TTM)||17.72|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Is Gilead Sciences (GILD) poised for a beat next week? Guggenheim analyst Tony Butler sees Gilead earning $2.15 a share, a penny above the consensus forecast compiled by sell-side analyst, with operating revenue of $6.54 billion beating the $6.31 billion expected by the Street. Butler’s estimates for the full 2017 calendar year are also above consensus, with per-share earnings of $8.28 on operating revenue of $25.4 billion.
Here are the activist investor's next potential targets.
Roche, Celgene and Novartis could change the multiple sclerosis landscape, a sector now dominated by Biogen.